BridgeBio Pharma stock is trading -18.78% below its average target price of $47.27 after marking a 4.0% during today's morning session. Analysts are giving the small-cap Pharmaceutical company an average rating of buy and target prices ranging from $28.0 to $60.0 per share.
BridgeBio Pharma has an elevated short interest of 16.0%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 8.74. Only 5.76% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. 94.9% of BridgeBio Pharma shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in BridgeBio Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Kohlberg Kravis Roberts & Co. L.P. | 18% | 31,060,971 | $1,192,585,995 |
| 2023-09-30 | Viking Global Investors, L.P. | 14% | 25,120,991 | $964,520,460 |
| 2023-09-30 | Vanguard Group Inc | 6% | 11,275,981 | $432,941,295 |
| 2023-09-30 | Blackrock Inc. | 5% | 9,249,943 | $355,151,565 |
| 2023-09-30 | Aisling Capital Management LP | 3% | 6,068,125 | $232,985,662 |
| 2023-09-30 | Laurion Capital Management, LP | 3% | 5,651,039 | $216,971,644 |
| 2023-09-30 | State Street Corporation | 3% | 5,040,414 | $193,526,697 |
| 2023-09-30 | Cormorant Asset Management, LP | 3% | 4,662,530 | $179,017,841 |
| 2023-09-30 | HHLR Advisors, LTD | 2% | 2,782,750 | $106,843,687 |
| 2023-09-30 | Pictet Asset Management Holding SA | 2% | 2,740,022 | $105,203,145 |
For these reasons, we consider that the BridgeBio Pharma is the subject of mixed market sentiment.
